Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity

Journal of Virology

Volumn 89, Issue 20, 2015, Pages 10383-10398

  Hu, Joyce K ^a,b   Crampton, Jordan C ^a,b   Cupo, Albert ^c   Ketas, Thomas ^c   van Gils, Marit J ^d   Sliepen, Kwinten ^d   de Taeye, Steven W ^d   Sok, Devin ^b,e,f   Ozorowski, Gabriel ^b,e   Deresa, Isaiah ^a,b   Stanfield, Robyn ^e   Ward, Andrew B ^b,e   Burton, Dennis R ^b,e,f   Klasse, Per Johan ^c   Sanders, Rogier W ^c,d   Moore, John P ^c   Crotty, Shane ^a,b,g  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f HARVARD UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; EPITOPE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING; RECOMBINANT PROTEIN; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISSOCIATION; EPITOPE MAPPING; GERMINAL CENTER; HELPER CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; SOLUBILITY; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; B-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; EPITOPES; GENE EXPRESSION; HEK293 CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; RECEPTORS, ANTIGEN, B-CELL; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 84942134414     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01653-15     Document Type: Article

References (91)

1. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol Principal Investigators Group, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
2. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
3. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol 86:4394-4403. http://dx.doi.org/10.1128/JVI.06973-11.
4. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang Z-Y, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, Comparative Sequencing Program NISC, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602. http://dx.doi.org/10.1126/science.1207532.
5. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Georgiev IS, Chuang G-Y, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, la Peña de AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138-142. http://dx.doi.org/10.1038/nature13601.
6. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109:18921-18925. http://dx.doi.org/10.1073/pnas.1214785109.
7. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PWHI, Marx PA, Burton DR. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-954. http://dx.doi.org/10.1038/nm.1974.
8. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433. http://dx.doi.org/10.1371/journal.ppat.1000433.
9. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y. 2014. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211:2061-2074. http://dx.doi.org/10.1084/jem.20132494.
10. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Principal Investigators PG, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
11. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu R-B, Fu BZ, Gnanapragasam PNP, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-138. http://dx.doi.org/10.1016/j.cell.2013.03.018.
12. West AP, Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. 2014. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156:633-648. http://dx.doi.org/10.1016/j.cell.2014.01.052.
13. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien J-P, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, John EPS, Chan-Hui P-Y, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P. 2013. The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies. PLoS Pathog 9:e1003754. http://dx.doi.org/10.1371/journal.ppat.1003754.
14. Victora GD, Nussenzweig MC. 2012. Germinal centers. Annu Rev Immunol 30:429-457. http://dx.doi.org/10.1146/annurev-immunol-020711-075032.
15. Crotty S. 2014. T follicular helper cell differentiation, function, and roles in disease. Immunity 41:529-542. http://dx.doi.org/10.1016/j.immuni.2014.10.004.
16. Gitlin AD, Shulman Z, Nussenzweig MC. 2014. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509:637-640. http://dx.doi.org/10.1038/nature13300.
17. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X, Pan L, Poholek A, Rao SS, Brenchley JM, Alam SM, Tomaras GD, Roederer M, Douek DC, Seder RA, Germain RN, Haddad EK, Koup RA. 2012. CD4 T follicular helper cell dynamics during SIV infection. J Clin Investig 122:3281-3294. http://dx.doi.org/10.1172/JCI63039.
18. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, Su LF, Cubas R, Davis MM, Sette A, Haddad EK, International AIDS Vaccine Initiative Protocol Principal Investigators Committee, Poignard P, Crotty S. 2013. Human circulating PD-1+ CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39:758-769. http://dx.doi.org/10.1016/j.immuni.2013.08.031.
19. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
20. Moore JP, Ho DD. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl A):S117-S136.
21. DeCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88:2489-2507. http://dx.doi.org/10.1128/JVI.02853-13.
22. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256.
23. Guttman M, Cupo A, Julien J-P, Sanders RW, Wilson IA, Moore JP, Lee KK. 2015. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun 6:6144. http://dx.doi.org/10.1038/ncomms7144.
24. Bartesaghi A, Merk A, Borgnia MJ, Milne JLS, Subramaniam S. 2013. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 20:1352-1357. http://dx.doi.org/10.1038/nsmb.2711.
25. Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 202:595-605. http://dx.doi.org/10.1086/654816.
26. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206:431-441. http://dx.doi.org/10.1093/infdis/jis367.
27. Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N, Kim HJ, Blattner C, la Peña de AT, Korzun J, Golabek M, de los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, Expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. http://dx.doi.org/10.1371/journal.ppat.1003618.
28. Lyumkis D, Julien J-P, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484-1490. http://dx.doi.org/10.1126/science.1245627.
29. Julien J-P, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477-1483. http://dx.doi.org/10.1126/science.1245625.
30. Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien J-P, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW. 2015. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog 11:e1004767. http://dx.doi.org/10.1371/journal.ppat.1004767.
31. Sok D, van Gils MJ, Pauthner M, Julien J-P, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, Hua Y, Seaman MS, Moore JP, Ward AB, Wilson IA, Sanders RW, Burton DR. 2014. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad SciUSA111:17624-17629. http://dx.doi.org/10.1073/pnas.1415789111.
32. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang G-Y, Ofek G, Stewart-Jones GBE, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-461. http://dx.doi.org/10.1038/nature13808.
33. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien J-P, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, Labranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 2015. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349:aac4223. http://dx.doi.org/10.1126/science.aac4223.
34. Liao H-X, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L, Comparative Sequencing Program NISC, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia S-M, Montefiori DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BTM, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469-476. http://dx.doi.org/10.1038/nature12053.
35. Streeck H, D'Souza MP, Littman DR, Crotty S. 2013. Harnessing CD4+ T cell responses in HIV vaccine development. Nat Med 19:143-149. http://dx.doi.org/10.1038/nm.3054.
36. Montefiori DC. 2001. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. John Wiley & Sons, Inc., Hoboken, NJ.
37. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
38. Code of Federal Regulations. 1989. Final rules: animal welfare act. 9 CFR parts 1, 2, and 3. U.S. Department of Agriculture, Washington, DC.
39. Waggoner SN, Cornberg M, Selin LK, Welsh RM. 2012. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481:394-398.
40. Yang H, Yogeeswaran G, Bukowski JF, Welsh RM. 1985. Expression of asialo GM1 and other antigens and glycolipids on natural killer cells and spleen leukocytes in virus-infected mice. Nat Immun Cell Growth Regul 4:21-39.
41. Chung NP, Matthews K, Kim HJ, Ketas TJ, Golabek M, de los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A. 2014. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology 11:33. http://dx.doi.org/10.1186/1742-4690-11-33.
42. Forsell MNE, Dey B, Mörner A, Svehla K, O'Dell S, Hogerkorp C-M, Voss G, Thorstensson R, Shaw GM, Mascola JR, Karlsson Hedestam GB, Wyatt RT. 2008. B cell recognition of the conserved HIV-1 coreceptor binding site is altered by endogenous primate CD4. PLoS Pathog 4:e1000171. http://dx.doi.org/10.1371/journal.ppat.1000171.
43. Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, Lao C, Crotty S. 2011. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 34:932-946. http://dx.doi.org/10.1016/j.immuni.2011.03.023.
44. Yang Q, Li C, Wei Y, Huang W, Wang L-X. 2010. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc. Bioconjug Chem 21:875-883. http://dx.doi.org/10.1021/bc9004238.
45. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470.
46. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
47. Daar ES, Li XL, Moudgil T, Ho DD. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 87:6574-6578. http://dx.doi.org/10.1073/pnas.87.17.6574.
48. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 66: 235-243.
49. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien J-P, Wilson IA, Klasse PJ, Ward AB, Moore JP. 2013. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 110:18256-18261. http://dx.doi.org/10.1073/pnas.1314351110.
50. Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de los Reyes K, Ketas TJ, Julien J-P, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP. 2015. A native-like SOSIP664 trimer based on an HIV-1 subtype B env gene. J Virol 89:3380-3395. http://dx.doi.org/10.1128/JVI.03473-14.
51. Tran K, Poulsen C, Guenaga J, de Val N, de Val Alda N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT. 2014. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A 111:E738-E747. http://dx.doi.org/10.1073/pnas.1319512111.
52. Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H. 2013. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 208:413-417. http://dx.doi.org/10.1093/infdis/jit178.
53. Ledgerwood JE, Zephir K, Hu Z, Wei C-J, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS, VRC 310 Study Team. 2013. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208:418-422. http://dx.doi.org/10.1093/infdis/jit180.
54. Strikas RA, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. 2015. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2015. MMWR Morb Mortal Wkly Rep 64:93-94.
55. Soldemo M, Pedersen GK, Hedestam GBK. 2014. HIV-1 Env-specific memory and germinal center B cells in C57BL/6 mice. Viruses 6:3400-3414. http://dx.doi.org/10.3390/v6093400.
56. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M, Lifson JD, Dimitrov D, Nussenzweig MC, Martin MA. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-280.
57. Plotkin SA, Orenstein WA, Offit PA. 2012. Vaccines, 6th ed. Elsevier, Philadelphia, PA.
58. Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner K-M. 2013. Germinal center B cells govern their own fate via antibody feedback. J Exp Med 210:457-464. http://dx.doi.org/10.1084/jem.20120150.
59. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159: 279-289.
60. Selvarajah S, Puffer BA, Lee F-H, Zhu P, Li Y, Wyatt R, Roux KH, Doms RW, Burton DR. 2008. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retrovir 24:301-314. http://dx.doi.org/10.1089/aid.2007.0158.
61. Yasmeen A, Ringe R, Derking R, Cupo A, Julien J-P, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11:41. http://dx.doi.org/10.1186/1742-4690-11-41.
62. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JLS, Wilson IA, Olson WC, Moore JP, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A 108:11440-11445. http://dx.doi.org/10.1073/pnas.1101414108.
63. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang G-Y, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang Z-Y, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang L-X, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343. http://dx.doi.org/10.1038/nature10696.
64. Kong L, Lee JH, Doores KJ, Murin CD, Julien J-P, Mcbride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20:796-803. http://dx.doi.org/10.1038/nsmb.2594.
65. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817. http://dx.doi.org/10.1126/science.1192819.
66. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, la Peña de AT, Cupo A, Julien J-P, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40:669-680. http://dx.doi.org/10.1016/j.immuni.2014.04.008.
67. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M. 2010. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84:1631-1636. http://dx.doi.org/10.1128/JVI.01482-09.
68. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937. http://dx.doi.org/10.1128/JVI.00758-09.
69. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85:11502-11519. http://dx.doi.org/10.1128/JVI.05363-11.
70. Stamatatos L, Morris L, Burton DR, Mascola JR. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15:866-870.
71. Wu L, Oficjalska K, Lambert M, Fennell BJ, Darmanin-Sheehan A, Ní Shúilleabháin D, Autin B, Cummins E, Tchistiakova L, Bloom L, Paulsen J, Gill D, Cunningham O, Finlay WJJ. 2012. Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids. J Immunol 188:322-333. http://dx.doi.org/10.4049/jimmunol.1102466.
72. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, III, Rader C. 2003. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325:325-335. http://dx.doi.org/10.1016/S0022-2836(02)01232-9.
73. Link JM, Larson JE, Schroeder HW. 2005. Despite extensive similarity in germline DH and JH sequence, the adult Rhesus macaque CDR-H3 repertoire differs from human. Mol Immunol 42:943-955. http://dx.doi.org/10.1016/j.molimm.2004.09.027.
74. Wu TT, Johnson G, Kabat EA. 1993. Length distribution of CDRH3 in antibodies. Proteins 16:1-7. http://dx.doi.org/10.1002/prot.340160102.
75. Yu L, Guan Y. 2014. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front Immunol 5:250.
76. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J, Stewart-Jones G, DeStefano J, O'Dell S, Labranche C, Robinson JE, Montefiori DC, McKee K, Du SX, Doria-Rose N, Kwong PD, Mascola JR, Zhu P, Schief WR, Wyatt RT, Whalen RG, Binley JM. 2015. Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog 11:e1004932. http://dx.doi.org/10.1371/journal.ppat.1004932.
77. Bonhomme CJ, Knopp KA, Bederka LH, Angelini MM, Buchmeier MJ. 2013. LCMV glycosylation modulates viral fitness and cell tropism. PLoS One 8:e53273. http://dx.doi.org/10.1371/journal.pone.0053273.
78. Pinschewer DD, Perez M, Jeetendra E, Bächi T, Horvath E, Hengartner H, Whitt MA, la Torre de JC, Zinkernagel RM. 2004. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Investig 114:988-993. http://dx.doi.org/10.1172/JCI200422374.
79. Eschli B, Zellweger RM, Wepf A, Lang KS, Quirin K, Weber J, Zinkernagel RM, Hengartner H. 2007. Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus. J Virol 81:11650-11657. http://dx.doi.org/10.1128/JVI.00955-07.
80. Battegay M, Moskophidis D, Waldner H, Bründler MA, Fung-Leung WP, Mak TW, Hengartner H, Zinkernagel RM. 1993. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J Immunol 151:5408-5415.
81. Hangartner L, Zinkernagel RM, Hengartner H. 2006. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231-243. http://dx.doi.org/10.1038/nri1783.
82. Bergthaler A, Flatz L, Verschoor A, Hegazy AN, Holdener M, Fink K, Eschli B, Merkler D, Sommerstein R, Horvath E, Fernandez M, Fitsche A, Senn BM, Verbeek JS, Odermatt B, Siegrist C-A, Pinschewer DD. 2009. Impaired antibody response causes persistence of prototypic T cellcontained virus. PLoS Biol 7:e1000080.
83. Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, Karlsson MCI, Mascola JR, Wyatt RT, Cancro MP, Karlsson Hedestam GB. 2012. BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol 188:6018-6026. http://dx.doi.org/10.4049/jimmunol.1200466.
84. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, Thinnes TC, Bhullar D, Briney B, Menis S, Jones M, Kubitz M, Spencer S, Adachi Y, Burton DR, Schief WR, Nemazee D. 2015. HIV-1 vaccines. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-161.
85. Dosenovic P, Boehmer von L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao K-H, Liu C, Gazumyan A, Seaman MS, Bjorkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC. 2015. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161:1505-1515. http://dx.doi.org/10.1016/j.cell.2015.06.003.
86. Lee E-C, Liang Q, Ali H, Bayliss L, Beasley A, Bloomfield-Gerdes T, Bonoli L, Brown R, Campbell J, Carpenter A, Chalk S, Davis A, England N, Fane-Dremucheva A, Franz B, Germaschewski V, Holmes H, Holmes S, Kirby I, Kosmac M, Legent A, Lui H, Manin A, O'Leary S, Paterson J, Sciarrillo R, Speak A, Spensberger D, Tuffery L, Waddell N, Wang W, Wells S, Wong V, Wood A, Owen MJ, Friedrich GA, Bradley A. 2014. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol 32:356-363. http://dx.doi.org/10.1038/nbt.2825.
87. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M, Mikulka W, Krueger P, Fairhurst J, Valenzuela DM, Papadopoulos N, Yancopoulos GD. 2014. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 111:5153-5158. http://dx.doi.org/10.1073/pnas.1324022111.
88. Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, Frendewey D, Valenzuela DM, Giallourakis CC, Alt FW, Yancopoulos GD, Murphy AJ. 2014. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A 111:5147-5152. http://dx.doi.org/10.1073/pnas.1323896111.
89. Schwickert TA, Victora GD, Fooksman DR, Kamphorst AO, Mugnier MR, Gitlin AD, Dustin ML, Nussenzweig MC. 2011. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med 208:1243-1252. http://dx.doi.org/10.1084/jem.20102477.
90. Gitlin AD, Mayer CT, Oliveira TY, Shulman Z, Jones MJK, Koren A, Nussenzweig MC. 2015. T cell help controls the speed of the cell cycle in germinal center B cells. Science 349:643-646.
91. Guttman M, Garcia NK, Cupo A, Matsui T, Julien J-P, Sanders RW, Wilson IA, Moore JP, Lee KK. 2014. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22:974-984. http://dx.doi.org/10.1016/j.str.2014.05.001.